The RNA-binding profile of the splicing factor SRSF6 in immortalized human pancreatic β-cells.
Maria Inês AlvelosMirko BrüggemannFx Reymond SutandyJonàs Juan-MateuMaikel Luis ColliAnke BuschMiguel LopesÂngela CastelaAnnemieke M Aartsma-RusJulian KönigKathi ZarnackDecio L EizirikPublished in: Life science alliance (2020)
In pancreatic β-cells, the expression of the splicing factor SRSF6 is regulated by GLIS3, a transcription factor encoded by a diabetes susceptibility gene. SRSF6 down-regulation promotes β-cell demise through splicing dysregulation of central genes for β-cells function and survival, but how RNAs are targeted by SRSF6 remains poorly understood. Here, we define the SRSF6 binding landscape in the human pancreatic β-cell line EndoC-βH1 by integrating individual-nucleotide resolution UV cross-linking and immunoprecipitation (iCLIP) under basal conditions with RNA sequencing after SRSF6 knockdown. We detect thousands of SRSF6 bindings sites in coding sequences. Motif analyses suggest that SRSF6 specifically recognizes a purine-rich consensus motif consisting of GAA triplets and that the number of contiguous GAA triplets correlates with increasing binding site strength. The SRSF6 positioning determines the splicing fate. In line with its role in β-cell function, we identify SRSF6 binding sites on regulated exons in several diabetes susceptibility genes. In a proof-of-principle, the splicing of the susceptibility gene LMO7 is modulated by antisense oligonucleotides. Our present study unveils the splicing regulatory landscape of SRSF6 in immortalized human pancreatic β-cells.
Keyphrases
- induced apoptosis
- transcription factor
- cell cycle arrest
- endothelial cells
- type diabetes
- cardiovascular disease
- single cell
- genome wide
- genome wide identification
- induced pluripotent stem cells
- oxidative stress
- endoplasmic reticulum stress
- poor prognosis
- metabolic syndrome
- cell death
- skeletal muscle
- bone marrow
- long non coding rna
- gene expression
- glycemic control
- copy number
- pluripotent stem cells
- cancer therapy
- mesenchymal stem cells